(2)卵巣癌の予後規程因子の同定とそれに基づく新たな分子標的治療の開発 : 腹膜播種の抑制に焦点を合わせて(<特集>第61回学術講演会シンポジウム3「卵巣癌の新たな治療戦略-基礎から,そして臨床から-」)
スポンサーリンク
概要
- 論文の詳細を見る
Ovarian cancer has the highest mortality rate of all gynecologic tumors. It is often diagnosed at a late stage, after tumor cells are disseminated within the peritoneal cavity. A current working model for the metastatic process of ovarian carcinoma suggests that cancer cells are shed from the ovarian tumor into the peritoneal cavity and attach to the layer of mesothelial cells that line the inner surface of the peritoneum. The key process is the initial attachment to the peritoneal cavity, and inhibiting the attachment of ovarian cancer cells might give us new insights to treat ovarian cancer. E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that downregulation of E-cadherin would affect expression of cell-matrix adhesion receptors. Herein, we show that inhibition of E-cadherin in ovarian cancer cells causes upregulation of α_5-integrin expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently, which was inhibited by α_5β_1-integrin blocking antibody. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of α_5-integrin, intraperitoneal treatment with an α_5β_1-integrin antibody significantly reduced tumor burden, ascites, number of metastasis. α_5-integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. 10 of 107 tissues (9%) had α_5-integrin overexpression and 39% had some level of α_5-integrin expression. The median survival for patients with high α_5-integrin levels was 26 months versus 35 months for these with low integrin expression (p<0.05). Taken together, we have identified α_5-integrin upregulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients. Next, we focused on hepatocyte growth factor receptor, c-Met, a receptor tyrosine kinase that plays an important role in tumor growth by activating mitogenic signaling pathways and regulating adhesion and invasion. C-Met protein expression was detected by immunohistochemistry in 138 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. 15 of 138 tissues (11%) had c-Met overexpression. Median survival for patients with high c-Met levels was 17 months versus 32 months (p=0.001) for these with low c-Met expression. Infection of SKOV-3ip1 cells with an adenovirus expressing a siRNA against c-Met efficiently inhibited c-Met protein and mRNA expression. It also inhibited adhesion to different extracellular matrix components and human primary mesothelial cells. This was paralleled by a significant reduction in α5- and β1-integrin protein and mRNA expression. In SKOV-3ip1 ovarian cancer xenografts, intraperitoneal treatment with the c-Met siRNA significantly reduced tumor burden, ascites formation, protease activity, and the number of peritoneal implants. These results suggest that c-Met overexpression is a prognostic factor in ovarian cancer, and that targeting c-Met in vivo inhibits peritoneal dissemination and invasion through an α5β1-integrin dependent mechanism. Therefore, c-Met should be explored further as a therapeutic target in ovarian cancer. In ovarian cancer, despite current aggressive treatments, such as debulking surgical cytoreduction and intensive chemotherapy, more than two thirds of all patients succumb to the disease within 5 years. Presently used anticancer drugs, even if they are very effective at killing cancer cells, can be used only at limited concentrations because of their toxicity to normal cells. Accordingly, it seems worthwhile to look for drugs that inhibit the progression of ovarian cancer focusing on peritoneal dissemination. The mechanisms presented here may provide the basis for a novel clinical application that controls the metastasis of ovarian cancer in the near future.
- 社団法人日本産科婦人科学会の論文
- 2009-11-01
著者
関連論文
- 4 月経周期を有する正常女性における月経関連片頭痛のアンケート調査(一般演題A「PMSおよび疼痛関連」,これからの女性心身医学におけるサイエンスとその展望:分子レベルから臨床医学まで,第39回日本女性心身医学会学術集会)
- K3-21 動脈スティフネスの非侵襲的測定による妊娠高血圧症候群の早期診断の可能性(高得点演題11 周産期,高得点演題プログラム,第62回日本産科婦人科学会学術講演会)
- 卵胞刺激ホルモン(FSH) (広範囲 血液・尿化学検査 免疫学的検査(第7版・4)その数値をどう読むか) -- (内分泌学的検査 間脳下垂体関係(subunitを含む))
- K3-28 胎児頭蓋内出血を来たした特発性血小板減少性紫斑病(Idiopathic Thrombocytopenic Purpura:ITP)合併妊娠の一症例(高得点演題12 周産期,高得点演題プログラム,第62回日本産科婦人科学会学術講演会)
- (2) 卵巣癌の予後規程因子の同定とそれに基づく新たな分子標的治療の開発 : 腹膜播種の抑制に焦点を合わせて(卵巣がんの新たな戦略-基礎から,そして臨床から-,シンポジウム3,第61回日本産科婦人科学会学術講演会)
- P2-212 mTORをターゲットとした卵巣明細胞腺癌の治療戦略(Group69 卵巣腫瘍4,一般演題,第62回日本産科婦人科学会学術講演会)
- P3-112 母体心停止後の胎児評価について : 縊頸にて最低20分の母体心停止があった後に搬送・分娩となった1症例(Group112 合併症妊娠7,一般演題,第62回日本産科婦人科学会学術講演会)
- P3-119 当施設でのもやもや病合併妊娠の予後に関する検討 : 妊娠中に出血症状により初めて診断されたもやもや病合併妊娠の1例を通じて(Group113 合併症妊娠8,一般演題,第62回日本産科婦人科学会学術講演会)
- P1-124 妊娠中に発見された横行結腸癌由来の腹膜偽粘液腫の一症例(Group16 合併症妊娠2,一般演題,第62回日本産科婦人科学会学術講演会)
- K3-45 ヒト絨毛癌細胞における低酸素下でのmetal transcription factor-1(MTF)によるPlacenta Growth Factor(PLGF)発現制御機構の検討(高得点周産期学8,高得点演題プログラム,第60回日本産科婦人科学会学術講演会)